Corbus Pharmaceuticals Holdings Overview
- Year Founded
-
2009
- Status
-
Public
- Employees
-
36
- Stock Symbol
-
CRBP
- Investments
-
1
- Share Price
-
$3.38
- (As of Friday Closing)
Corbus Pharmaceuticals Holdings General Information
Description
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
Contact Information
Website
www.corbuspharma.comCorporate Office
- 500 River Ridge Drive
- Norwood, MA 02062
- United States
Corporate Office
- 500 River Ridge Drive
- Norwood, MA 02062
- United States
Corbus Pharmaceuticals Holdings Stock Performance
As of 13-Nov-2026, Corbus Pharmaceuticals Holdings’s stock price is $3.38. Its current market cap is $69.9M with 20.6M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $3.38 | $3.40 | $2.81 - $12.88 | $69.9M | 20.6M | 1.07M | -$6.12 |
Corbus Pharmaceuticals Holdings Financials Summary
As of 30-Sep-2026, Corbus Pharmaceuticals Holdings has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 18,231 | 40,949 | (12,034) | 20,843 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (121,170) | (83,834) | (44,060) | (41,741) |
| Net Income | (116,315) | (78,537) | (40,209) | (44,604) |
| Total Assets | 122,902 | 168,195 | 155,879 | 28,272 |
| Total Debt | 3,909 | 1,633 | 3,239 | 20,885 |
Corbus Pharmaceuticals Holdings Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Corbus Pharmaceuticals Holdings Comparisons
Industry
Financing
Details
Corbus Pharmaceuticals Holdings Competitors (56)
One of Corbus Pharmaceuticals Holdings’s 56 competitors is Capricor Therapeutics, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Capricor Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Geron | Formerly VC-backed | Foster City, CA | ||||
| etherna | Formerly VC-backed | Niel, Belgium | ||||
| Lisata Therapeutics | Corporation | Basking Ridge, NJ |
Corbus Pharmaceuticals Holdings Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Corbus Pharmaceuticals Holdings Patents
Corbus Pharmaceuticals Holdings Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260335286-A1 | Compositions and methods for treating weight conditions | Pending | 26-Mar-2025 | ||
| WO-2026207199-A1 | Compositions and methods for treating weight conditions | Pending | 26-Mar-2025 | ||
| US-20260124199-A1 | Cannabinoid receptor 1 antagonists/inverse agonists and uses thereof | Pending | 06-Nov-2024 | ||
| WO-2026102129-A1 | Cannabinoid receptor 1 antagonists/inverse agonists and uses thereof | Pending | 06-Nov-2024 | ||
| US-20260092038-A1 | Cannabinoid receptor 1 antagonists/inverse agonists and uses thereof | Pending | 27-Sep-2024 | A61K38/26 |
Corbus Pharmaceuticals Holdings Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Corbus Pharmaceuticals Holdings Acquisitions (1)
Corbus Pharmaceuticals Holdings’s most recent deal was a Merger/Acquisition with JB Therapeutics. The deal was made on 21-Apr-2014.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| JB Therapeutics | 21-Apr-2014 | Merger/Acquisition | Drug Discovery |
Corbus Pharmaceuticals Holdings ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Corbus Pharmaceuticals Holdings FAQs
-
When was Corbus Pharmaceuticals Holdings founded?
Corbus Pharmaceuticals Holdings was founded in 2009.
-
Where is Corbus Pharmaceuticals Holdings headquartered?
Corbus Pharmaceuticals Holdings is headquartered in Norwood, MA.
-
What is the size of Corbus Pharmaceuticals Holdings?
Corbus Pharmaceuticals Holdings has 36 total employees.
-
What industry is Corbus Pharmaceuticals Holdings in?
Corbus Pharmaceuticals Holdings’s primary industry is Drug Discovery.
-
Is Corbus Pharmaceuticals Holdings a private or public company?
Corbus Pharmaceuticals Holdings is a Public company.
-
What is Corbus Pharmaceuticals Holdings’s stock symbol?
The ticker symbol for Corbus Pharmaceuticals Holdings is CRBP.
-
What is the current stock price of Corbus Pharmaceuticals Holdings?
As of 13-Nov-2026 the stock price of Corbus Pharmaceuticals Holdings is $3.38.
-
What is the current market cap of Corbus Pharmaceuticals Holdings?
The current market capitalization of Corbus Pharmaceuticals Holdings is $69.9M.
-
Who are Corbus Pharmaceuticals Holdings’s competitors?
Capricor Therapeutics, CytomX Therapeutics, Geron, etherna, and Lisata Therapeutics are some of the 56 competitors of Corbus Pharmaceuticals Holdings.
-
What is Corbus Pharmaceuticals Holdings’s annual earnings per share (EPS)?
Corbus Pharmaceuticals Holdings’s EPS for 12 months was -$6.12.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
